N-Acetyl Semax Amidate: An Improved Nootropic Peptide

N-Acetyl Semax Amidate: An Improved Nootropic Peptide

Introduction

N-Acetyl Semax Amidate is an acetylated form of the nootropic peptide Semax, developed to enhance pharmacokinetic stability and resistance to enzymatic degradation. This advanced formulation could offer significant benefits for brain health and cognitive function. This article delves into the properties, potential benefits, and research surrounding N-Acetyl Semax Amidate.


What Is N-Acetyl Semax Amidate?

N-Acetyl Semax Amidate is an improved version of Semax, a nootropic peptide created by Russian researchers in the 1980s. Both peptides share a seven-amino-acid sequence, with a portion of adrenocorticotropic hormone (ACTH 4-7) fused to a Pro-Gly-Pro extension at the C-terminus. This structure allows Semax to cross the blood-brain barrier (BBB) and exert its nootropic effects without significant endocrine side effects.

N-Acetyl Semax Amidate integrates acetic acid at the N-terminus and amidation at the C-terminus, protecting the peptide from hydrolysis and degradation. This modification enhances its stability in brain tissue, potentially extending its nootropic effects by up to 30 minutes compared to Semax.


Potential Benefits of N-Acetyl Semax Amidate

Neuroprotection

Research suggests that Semax, and by extension N-Acetyl Semax Amidate, may increase neurotrophic factors that promote neuronal survival and plasticity. These include brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Studies indicate that Semax exposure can raise BDNF levels by 40% and potentially induce a 100% increase in the brain's tropomyosin receptor kinase B (TrkB) receptor expression. These receptors mediate many of BDNF's neuroprotective effects.

Cognitive Enhancement

N-Acetyl Semax Amidate may improve cognitive function, especially under conditions of cognitive load and stress. Animal studies have shown that Semax significantly enhances brain activity in the Default Mode Network (DMN), particularly in the medial frontal cortex, which is associated with better information processing and episodic memory. Additionally, research models exposed to Semax after prolonged stress exhibited significantly improved performance in memory tests.


Beyond the Brain: Potential Systemic Benefits

Ulcer Healing

Like Semax, N-Acetyl Semax Amidate may have benefits outside the nervous system. Studies suggest that Semax can accelerate the healing of peptic ulcers by regulating blood flow and enhancing vascular function. Although further investigation is needed, N-Acetyl Semax Amidate may offer similar therapeutic potential.


Current Research and Future Directions

While N-Acetyl Semax Amidate shows promise, its mechanisms and effects are not well studied. Most available data focus on its pharmacokinetics, indicating improved stability and prolonged activity compared to Semax. However, comprehensive research is required to fully understand its pharmacodynamics and potential therapeutic applications.


Conclusion

N-Acetyl Semax Amidate represents a significant advancement in nootropic peptides, offering improved stability and potentially enhanced neuroprotective and cognitive benefits. As research continues to unfold, this peptide may become a valuable tool in the quest for better brain health and cognitive function.

For researchers and enthusiasts interested in exploring the potential of N-Acetyl Semax Amidate, high-quality research peptides can be purchased from reputable suppliers like Biotech Peptides.


References

  1. Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., & Myasoedov, N. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine, 4(04), 223-252.
  2. Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland), 14(6), 515.
  3. Tsai S. J. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical hypotheses, 68(5), 1144–1146.
  4. Shevchenko, K. V., Nagaev, I. Y., Andreeva, L. A., Shevchenko, V. P., & Myasoedov, N. F. (2019). Prospects for Intranasal Delivery of Neuropeptides to the Brain. Pharmaceutical Chemistry Journal, 53, 89-100.
  5. Markov, D. D., Dolotov, O. V., & Grivennikov, I. A. (2023). The Melanocortin System: A Promising Target for the Development of New Antidepressant Drugs. International journal of molecular sciences, 24(7), 6664.
  6. Shevchenko, K. V., Nagaev, I. Y., Andreeva, L. A., Shevchenko, V. P., & Myasoedov, N. F. (2013). Stability of Semax acetyl to proteolysis in various biological media. Doklady biological sciences: proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 449, 110–112.
  7. Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of molecular neuroscience: MN, 41(1), 30–35.
  8. Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research, 1117(1), 54–60.
  9. https://www.moroccoworldnews.com/2024/06/363041/n-acetyl-semax-amidate-study-guide

Read More Articles at PKatGlance

Post a Comment

Previous Post Next Post